Jubilant Ingrevia Ltd
Jubilant Ingrevia, a global integrated Life Science products and Innovative Solutions provider serving, Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers with our customised products and solutions that are innovative, cost-effective and conforming to excellent quality standards.
Jubilant Ingrevia’s portfolio also extends to custom research and manufacturing for pharmaceutical and agrochemical customers on an exclusive basis. [1]
- Market Cap ₹ 8,561 Cr.
- Current Price ₹ 539
- High / Low ₹ 582 / 379
- Stock P/E 46.8
- Book Value ₹ 172
- Dividend Yield 0.93 %
- ROCE 9.78 %
- ROE 6.77 %
- Face Value ₹ 1.00
Pros
- Company has been maintaining a healthy dividend payout of 28.6%
Cons
- Company has a low return on equity of 13.1% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
0 | 684 | 4,949 | 4,773 | 4,136 | |
0 | 567 | 4,108 | 4,224 | 3,715 | |
Operating Profit | -0 | 117 | 841 | 549 | 421 |
OPM % | 17% | 17% | 11% | 10% | |
0 | -10 | 22 | 32 | 35 | |
Interest | 0 | 7 | 31 | 22 | 53 |
Depreciation | 0 | 22 | 123 | 122 | 136 |
Profit before tax | -0 | 77 | 709 | 437 | 268 |
Tax % | 0% | 30% | 33% | 30% | 32% |
-0 | 54 | 477 | 308 | 183 | |
EPS in Rs | -3.40 | 3.41 | 29.93 | 19.31 | 11.48 |
Dividend Payout % | 0% | 10% | 17% | 26% | 43% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 82% |
TTM: | -13% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 42% |
TTM: | -41% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 8% |
1 Year: | 36% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 13% |
Last Year: | 7% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Equity Capital | 0 | 16 | 16 | 16 | 16 |
Reserves | -0 | 1,907 | 2,417 | 2,650 | 2,722 |
0 | 556 | 238 | 407 | 740 | |
0 | 888 | 1,111 | 1,176 | 1,254 | |
Total Liabilities | 0 | 3,366 | 3,782 | 4,249 | 4,732 |
0 | 1,805 | 1,798 | 1,846 | 2,539 | |
CWIP | 0 | 65 | 174 | 525 | 331 |
Investments | 0 | 50 | 6 | 8 | 16 |
0 | 1,446 | 1,804 | 1,870 | 1,846 | |
Total Assets | 0 | 3,366 | 3,782 | 4,249 | 4,732 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
0 | 112 | 453 | 462 | 430 | |
0 | 33 | -71 | -469 | -569 | |
0 | -72 | -418 | 42 | 144 | |
Net Cash Flow | 0 | 73 | -36 | 35 | 5 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Debtor Days | 251 | 43 | 39 | 50 | |
Inventory Days | 601 | 117 | 146 | 160 | |
Days Payable | 685 | 103 | 113 | 131 | |
Cash Conversion Cycle | 167 | 57 | 72 | 80 | |
Working Capital Days | 269 | 59 | 61 | 64 | |
ROCE % | 8% | 29% | 16% |
Documents
Announcements
- Intimation Of Record Date For Maturity Of Commercial Papers 1h
- Announcement under Regulation 30 (LODR)-Issue of Securities 1h
- Intimation Of Repayment Of Commercial Papers 1h
- Certificate Under Chapter XVII Of SEBI Operational Circular Dated August 10, 2021 1h
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
1d - Copy of Newspaper publication of Audited standalone and consolidated financial results of the Company for the quarter and year ended March 31, 2024.
Annual reports
Concalls
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT REC
-
Jul 2023Transcript PPT REC
-
Jul 2023TranscriptNotesPPT
-
May 2023Transcript PPT
-
May 2023TranscriptNotesPPT
-
Feb 2023TranscriptPPT
-
Feb 2023TranscriptPPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022TranscriptPPT
-
Mar 2022TranscriptNotesPPT
-
Mar 2022TranscriptNotesPPT
-
Feb 2022TranscriptPPT
-
Oct 2021TranscriptNotesPPT
-
Sep 2021TranscriptNotesPPT
-
Aug 2021TranscriptPPT
-
Jun 2021Transcript PPT
-
May 2021TranscriptPPT
Leadership[1]
# 40+ years of legacy in Chemicals space, started in 1978
# Global player in Pyridine + Beta, Vitamin B3 and Acetic Anhydride.
# Serves 15 of the top 20 Global Pharma & 7 of the top 10 Global Agrochemical companies.
# Leading Low-Cost provider